Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn, a clinical stage pharmaceutical company commercializing potential oncology and CNS therapeutics, has announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117. It is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis.
Subscribe to our email newsletter
Chang Ahn, chairman and chief executive officer of Rexahn, said: “In addition to our co-development partnership with Teva, this European patent award further validates the commercial potential of RX-3117. The development of RX-3117 strengthens our oncology pipeline, which includes ArchexinTM, currently in Phase II clinical trials.”
Potential indications of RX-3117 are solid tumors including colon, lung and pancreatic cancers. In preclinical trials, RX-3117 has demonstrated its ability to overcome cancer drug resistance in cancer cells, in particular, gemcitabine-resistance in the human lung cancer cell. The US patent issued for RX-3117 claims composition of matter, synthesis, and methods.
In September 2009, Rexahn announced a commercialization and development agreement with Teva for RX-3117. Under the agreement, Rexahn will be eligible to receive additional development, regulatory and sales milestone payments and royalties on net sales worldwide.